I have just read an interesting article on www.firstwordpluss.com that I wanted to share with you.
“The pharmaceutical industry agreed to a proposal to provide drug discounts to US Medicare beneficiaries that could be worth up to $80 billion over the next ten years. The proposal, which is part of a health-care bill drafted by US lawmakers on June 19, aims to reduce the coverage gap that affects recipients once their drug costs reach a certain level”
Its part of the sign that the USA is moving away from being the golden goose drug market that many have known for years and is moving to a more European model for health markets, this was inevitable and matches some of the predictions previously published on this site (see here). Its inevitable that as health care budgets become a larger part of national spending this kind of trend is only going to become more apparent.
More on the article
“As part of the deal that was negotiated between PhRMA and lawmakers, drugmakers would “provide a 50-percent discount to most beneficiaries on brand-name medicines covered by a patient’s Part D plan when purchased in the coverage gap,” according to industry representatives. In addition, the entire cost of the medicine purchased in the coverage gap will count towards the Medicare recipient’s out-of-pocket expenses.”
If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com
Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Grow your Expertise for Free
As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.
For Assistance with Regulatory Planning and Exicution of Clinical Trials Click Here
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!
Fill Out the Short Form Below… |
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Pingback: Drug Patent Settlements Cost Consumers US$3.5bn annualy in the USA | Drug Development Consultant and Regulatory Consultant